C Diff Drug Development

Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind the revolutionary mRNA vaccines that tackled the coronavirus that caused COVID-19.

Discover the groundbreaking mRNA vaccine developed by University of Pennsylvania and Children's Hospital of Philadelphia to prevent and treat C. difficile

CP101 was superior to placebo in reducing recurrent CDI with a safety profile similar to placebo. https://clinicaltrials.gov/study/NCT03110133.

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection, more commonly known as C. difficile or C. diff. In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote clearance of existing C. diff bacteria from the gut, and even overcome deficits in host immunity to protect animals after infection, according to researchers. The results will pave the way for clinical trials of the vaccine.

There is growing interest in developing monotherapy drugs that treat inflammation caused by microbial infections, focusing on dual antimicrobial and anti-inflammatory agents with minimal side effects and high safety margins. This study synthesized and characterized a library of novel cis-4-ferroceny …

PHILADELPHIA – A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides difficile infection,

The study indicates that targeting the sympathetic nervous system could improve CDI management, as a novel multi-target mRNA vaccine was shown to protect mice from lethal doses.

Clostridioides difficile is traditionally isolated from healthcare facilities' inpatients, but it is increasingly being identified in people who have not recently been hospitalized and is more and more found in community settings. Investigators from Perelman School of Medicine at University of Pennsylvania developed an mRNA-LNP vaccine with promising results in preventing and controlling C. difficile infection.

CHARLOTTESVILLE, Va. (CBS19 NEWS) -- New research from the UVA School of Medicine has unveiled a potential way to fight C. difficile, which has been described as "a deadly plague"

CP101 was superior to placebo in reducing recurrent CDI with a safety profile similar to placebo. https://clinicaltrials.gov/study/NCT03110133.

Seres Therapeutics (NASDAQ:MCRB) announced Tuesday that Nestlé Health Science, a unit of consumer care giant Nestle (OTCPK:NSRGY), has agreed to purchase its oral microbiome therapy Vowst for $175M. However, shares of the Cambridge, Massachusetts-based biotech fell ~21% in reaction. Developed by Seres (MCRB) and Nestlé Health Science, Vowst was app...

A large team of microbiologists, pathologists and infectious diseases specialists affiliated with several institutions in the U.S. has developed an mRNA vaccine that has thus far been found able to protect mice against intestinal Clostridioides difficile bacterial infections.

Clostridium difficile (C. difficile) is one of the most threatening bacteria globally, causing high mortality and morbidity in humans and animals, and is considered a public health threat that requires urgent and aggressive action. Interruption of the human gut microbiome and the development of anti

Clostridioides difficile infection (CDI) is an urgent public health threat with limited preventative options. In this work, we developed a messenger RNA (mRNA)-lipid nanoparticle (LNP) vaccine targeting C. difficile toxins and virulence factors. This multivalent vaccine elicited robust …

Nature Communications - Xinchen Lv and colleagues design pan-specific protein mini-binders that neutralize Clostridioides difficile toxin B (TcdB) and solve TcdB-binder complex structures via...

Toxins TcdA and TcdB are the main virulence factors of Clostridioides difficile, a leading cause of hospital-acquired diarrhea. Despite their importance, there is a significant knowledge gap of druggable targets for inhibiting toxin production. To address this, we screened non-antibiotic phytochemic …

Acurx reports ibezapolstat's positive microbiome effects and Anthrax activity

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

Clostridioides difficile, a gram-positive, toxin-producing, spore-forming anaerobe, is a major cause of antibiotic-associated diarrhoea. The bacterium's intrinsic drug resistance limits current treatment options to fidaxomicin and vancomycin for initial episodes, with anti-toxin B monoclonal antibod …

Acurx readies ibezapolstat for Phase 3 CDI trials

The Clostridium Difficile Infections market is expected to surge due to the disease s increasing prevalence and awareness during the forecast period Furthermore launching various multiple stage Clostridium Difficile Infections pipeline products will significantly revolutionize the Clostridium Difficile Infections market ...

Dr. Abiola Olaitan has received $150,000 from the Canadian Foundation for Innovation’s John R. Evans Leaders Fund (CFI-JELF).

Postbiotics' ability to inhibit bacterial growth, biofilm disruption, and toxin reduction makes them a promising adjunctive for CDI treatment and a good solution to pathogens' antibiotic resistance.

An experimental vaccine failed to prevent Clostridioides difficile infection in a phase 3 trial but successfully reduced the duration of symptoms, infections requiring medical attention and antibiotic treatments, researchers reported.

Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Crestone Pharmaceuticals recently shared topline results from a phase 2 trial of its investigational drug treatment for Clostridioides difficile infection.

The small-molecule protein synthesis inhibitor CRS3121 met its primary endpoints, with high rates of clinical cure at day 12 and low rates of CDI recurrence.

Polyphenols have been reported to inhibit C. difficile growth and toxin production by several mechanisms in preclinical studies. However, more clinical studies are needed to investigate their safety in humans.

BOULDER, Colo.--(BUSINESS WIRE)--Sep 5, 2024--

CRS3123 is a novel, small molecule, antibiotic drug candidate that selectively inhibits 1 form of the bacterial methionyl-tRNA synthetase enzyme and is not affected by resistance to any existing classes of antibiotics.